Inhibikase Therapeutics, Inc.
IKT
$2.09
-$0.16-7.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | 7.19M | 4.19M | 3.08M | 2.75M | 3.00M |
| Gross Profit | -7.19M | -4.19M | -3.08M | -2.75M | -3.00M |
| SG&A Expenses | 5.74M | 1.64M | 1.97M | 2.03M | 1.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.93M | 5.83M | 5.05M | 4.78M | 4.40M |
| Operating Income | -12.93M | -5.83M | -5.05M | -4.78M | -4.40M |
| Income Before Tax | -12.13M | -5.78M | -4.96M | -4.65M | -4.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.13M | -5.78M | -4.96M | -4.65M | -4.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.13M | -5.78M | -4.96M | -4.65M | -4.18M |
| EBIT | -12.93M | -5.83M | -5.05M | -4.78M | -4.40M |
| EBITDA | -12.92M | -5.82M | -5.04M | -4.78M | -4.40M |
| EPS Basic | -0.17 | -0.65 | -0.66 | -0.73 | -0.68 |
| Normalized Basic EPS | -0.11 | -0.41 | -0.41 | -0.46 | -0.42 |
| EPS Diluted | -0.17 | -0.65 | -0.66 | -0.73 | -0.68 |
| Normalized Diluted EPS | -0.11 | -0.41 | -0.41 | -0.46 | -0.42 |
| Average Basic Shares Outstanding | 72.07M | 8.88M | 7.54M | 6.34M | 6.18M |
| Average Diluted Shares Outstanding | 72.07M | 8.88M | 7.54M | 6.34M | 6.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |